Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2025-04-27 Governance Information
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
[临时公告]德源药业:公司章程
Governance Information Classification · 100% confidence The document is titled "江苏德源药业股份有限公司章程" which translates to "Articles of Association of Jiangsu Deyuan Pharmaceutical Co., Ltd." It contains detailed chapters and sections about the company's general provisions, business scope, shares issuance and transfer, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution, auditing, notifications, mergers, capital changes, dissolution, liquidation, information disclosure, investor relations management, and amendments to the articles. The content is a comprehensive governance document outlining the company's internal rules, board structure, shareholder rights, and corporate governance practices. There is no indication that this is an announcement or a report publication notice; it is the actual articles of association document. This fits the definition of Governance Information (CGR) which details the company's internal rules and governance practices.
2025-04-27 Chinese
2024年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2024 Annual General Meeting (AGM) of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on shareholder meeting proceedings and voting outcomes rather than the full annual report or financial statements themselves. The document is not the annual report but an official announcement of the AGM resolutions and voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6666 characters) and detailed voting results support this classification with high confidence.
2025-04-27 Chinese
第四届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 12th meeting of the 4th Board of Directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes details about the meeting's time, place, attendance, and voting results. The key agenda item was the approval of the company's 2025 first quarter report, which is stated to be published on the Beijing Stock Exchange website with a separate announcement number. The document itself does not contain the financial data or the full quarterly report but rather announces the board's approval of that report. The document length is short (1001 characters), and it serves as a meeting resolution announcement rather than the report itself. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2025-04-27 Chinese
第四届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the approval of the company's 2025 first quarter report. It states that the quarterly report is published on the Beijing Stock Exchange website with a separate announcement number (2025-035). The document itself does not contain the financial data or substantive analysis of the quarterly report but only the meeting resolution approving it. The document length is short (856 characters) and serves as an announcement of the meeting decision rather than the report itself. Therefore, it fits best under the category of Regulatory Filings (RNS), as it is a formal announcement related to corporate governance and report approval but not the report itself.
2025-04-27 Chinese
国浩律师（南京）事务所关于江苏德源药业股份有限公司2024年年度股东会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, and voting procedures of the 2024 Annual General Meeting (AGM) of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the legality and compliance of the AGM process, including the announcement, attendance, voting results, and resolutions passed. The document does not contain financial statements or detailed financial performance data but focuses on the AGM procedures and legal compliance. The document length is 3641 characters, which is relatively short and consistent with a legal opinion or meeting-related document rather than a full annual report or financial report. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions on the meeting.
2025-04-27 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record" and it details a performance explanation meeting held on April 14, 2025, discussing the company's 2024 annual results and future plans. It includes detailed financial data such as revenue, net profit, R&D expenses, and operational updates. The document is a transcript or record of a performance explanation meeting (业绩说明会), which aligns with the definition of a Call Transcript (CT) as it is a full text record of a company communication event with investors discussing financial results and Q&A. The document length is 2824 characters, which is consistent with a transcript or meeting record rather than a full Annual Report or Interim Report. It is not an announcement or a brief summary but a detailed Q&A session. Therefore, the best classification is Call Transcript (CT).
2025-04-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.